5 Emerging HER2 Agents Changing Treatment Strategies
HER2-directed therapy has transformed outcomes for patients with HER2-driven cancers, and 2024 is shaping up to be another inflection point. Advances in antibody–drug conjugates (ADCs), bispecific antibodies, and more selective tyrosine kinase inhibitors are expanding options beyond classic trastuzumab-based regimens and extending benefit into HER2-low disease and tumor types such as gastric and biliary tract cancers. Clinicians and patients now face more nuanced choices: selecting agents by prior exposures, CNS activity, tolerability, and HER2 expression level. This article examines five emerging HER2 agents that are reshaping treatment strategies and highlights practical differences that matter for real-world decision-making.
Why trastuzumab deruxtecan (T-DXd) remains a practice-changing ADC
Trastuzumab deruxtecan (T-DXd) has become a cornerstone ADC by pairing a HER2-directed antibody with a potent topoisomerase I payload and a cleavable linker that can produce a bystander effect. Initially approved for HER2-positive metastatic breast cancer, T-DXd’s durable responses in the DESTINY clinical program led to expanded indications, including activity in HER2-low tumors. Its efficacy across varying HER2 expression has prompted rethinking of biomarker thresholds and sequencing: where once HER2 positivity alone guided therapy, clinicians now consider T-DXd for patients with lower-level expression after prior lines of therapy. Monitoring and managing interstitial lung disease (ILD) and hematologic effects remain essential components of treatment planning with this agent.
How tucatinib is changing the approach to HER2 brain metastases
Tucatinib is a highly selective HER2 tyrosine kinase inhibitor (TKI) that has altered expectations for intracranial disease control. In randomized data from the HER2CLIMB trial, adding tucatinib to trastuzumab and capecitabine improved progression-free and overall survival and demonstrated clinically meaningful intracranial responses in patients with brain metastases. That CNS activity has made tucatinib-containing regimens a preferred option when central nervous system disease is present or at high risk, and has influenced sequencing decisions for systemic therapy. Practical considerations include monitoring for diarrhea and hepatic transaminase elevations and selecting combinations that balance systemic control with tolerability.
What zanidatamab’s bispecific design brings to HER2-targeted therapy
Zanidatamab (ZW25) is a bispecific antibody that binds two distinct HER2 epitopes simultaneously, promoting receptor clustering, enhanced internalization, and immune-mediated cytotoxicity. Early- and mid-phase trials have shown promising single-agent activity in HER2-expressing biliary tract, gastric, and breast cancers, prompting ongoing phase III programs. The bispecific approach broadens the mechanistic toolkit beyond classical monoclonal antibodies and ADCs, offering potential efficacy in tumors with heterogeneous HER2 expression. Safety profiles to date are generally manageable, with infusion-related events and fatigue among common adverse effects, but larger randomized data are needed to define its optimal place in therapy.
Why disitamab vedotin and ARX788 are notable next-generation ADCs
Disitamab vedotin (RC48) and ARX788 represent two different strategies in the wave of next-generation HER2 ADCs. Disitamab vedotin links a HER2-targeting antibody to MMAE and has gained regulatory approval in China for HER2-expressing gastric cancer; its favorable activity in several tumor types has accelerated international development. ARX788 uses a site-specific conjugation technology designed to improve stability and therapeutic index and has shown activity in heavily pretreated HER2-positive and HER2-low cohorts in early-phase studies. These agents expand options for patients who have progressed on prior HER2-directed therapies and illustrate how payload choice, linker chemistry, and conjugation method influence efficacy and tolerability.
How the new HER2 agents compare: mechanisms, status and clinical considerations
| Agent | Mechanism | Clinical status (as of 2024) | Key evidence/considerations |
|---|---|---|---|
| Trastuzumab deruxtecan (T-DXd) | ADC (topo I payload, cleavable linker) | Approved for HER2+; expanded use in HER2-low breast cancer | Strong DESTINY program data; ILD risk requires monitoring |
| Tucatinib | Selective HER2 TKI | Approved in combination regimens for HER2+ metastatic breast cancer | Proven intracranial activity (HER2CLIMB); diarrhea and LFT monitoring |
| Zanidatamab (ZW25) | Bispecific anti-HER2 antibody (dual-epitope) | Promising phase II results; ongoing phase III trials | Activity in biliary tract and gastric cancers; bispecific biology |
| Disitamab vedotin (RC48) | ADC (MMAE payload) | Approved in China; global development ongoing | Active in gastric and urothelial contexts; tolerability similar to other ADCs |
| ARX788 | Site-specific HER2 ADC (novel linker/conjugate) | Early-phase efficacy signals; phase II/III trials underway | Designed for improved therapeutic index; data maturing in multiple indications |
What this means for clinicians and patients choosing HER2 therapy
Collectively, these agents expand the therapeutic landscape and require individualized decision-making that considers prior therapies, HER2 expression level, organ-specific disease (notably the brain), toxicity profiles, and patient goals. Innovations such as bispecific antibodies and newer ADC platforms are reducing the binary notion of HER2-positive versus HER2-negative disease by demonstrating benefit across a spectrum of expression. For patients, that means more options but also a greater need for multidisciplinary discussion and careful monitoring for class-specific toxicities, including pulmonary, hepatic, and neuropathic effects. Clinicians should follow evolving guidance from professional societies and the latest trial data when sequencing these treatments.
Medical disclaimer: This article summarizes evolving clinical data and should not replace individualized medical advice. Treatment choices depend on a patient’s full clinical context; consult oncology specialists and authoritative regulatory information for prescribing and safety details.
This text was generated using a large language model, and select text has been reviewed and moderated for purposes such as readability.
